Last reviewed · How we verify
ATI-045
ATI-045 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
ATI-045 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | ATI-045 |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | PI3K delta and PI3K gamma inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, ATI-045 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune conditions.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Injection site reactions
- Headache
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATI-045 CI brief — competitive landscape report
- ATI-045 updates RSS · CI watch RSS
- Aclaris Therapeutics, Inc. portfolio CI